Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nymox says data supports Alzheimer's disease test, get $15m for BHP

This article was originally published in Clinica

Executive Summary

A paper published in the January 2008 issue of Expert Review of Molecular Diagnostics concludes that Nymox Pharmaceutical's AlzheimAlert urine test "adds significant useful information in the diagnosis of Alzheimer's disease particularly for the family physician". The FDA has repeatedly refused to grant US marketing authorisation for the test, which detects strands of neural thread protein in urine (see Clinica No 1168, p 20). Nymox markets the test in Europe and offers it in the US as a CLIA-certified diagnostic service. Separately, the company said it had secured $15m in financial commitments. Nymox said it will use the funds to develop its NX-1207 drug for benign prostate hyperplasia and other new products.

You may also be interested in...

Aducanumab Review: Looking For Precedents – Long Ago And Far Afield

The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.

The Rebate Rule May Not Last, But It Changed The Pricing Debate

Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.

Moderna Gets To Watch And Learn From Pfizer’s COVID-19 Vaccine Advisory Committee

US FDA will simultaneously review the vaccines, with Moderna’s advisory committee set a week after Pfizer’s. ACIP emergency meeting scheduled for 1 December with vote likely on distribution priority for health care personnel.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts